Diego Zaquera Carvalho, M.D., M.S.

The purpose of this study is to evaluate whether enhancing systemic lymphatic drainage using an automated manual lymphatic drainage therapy (AMLDT) device⁷ can improve glymphatic clearance in patients with OSA, as measured by changes in serum biomarkers related to AD pathology (Aβ42, Aβ40, Aβ42/Aβ40 ratio, and p-tau-217), neurodegeneration/white matter integrity (neurofilament light chain), and neuroinflammation (glial fibrillary acidic protein). The AMLDT device (Neuroglide) is a FDA-cleared Class II medical device (K202693) for over-the-counter use for pain.⁸ It mimics manual lymphatic drainage through a pneumatic mat that performs rhythmic inflation and deflation in ascending fashion.

The purpose of this study is to identify the association between untreated OSA and chronic insomnia and their association with cognitive decline, increased Alzheimer's Disease (AD) and vascular pathology.